Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016600 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01016600 is a Phase 1 study of Leukemia, Myeloid, Acute that has completed, run by Washington University School of Medicine. The registered enrollment target is 31 participants, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01016600, a Phase 1 study of Leukemia, Myeloid, Acute, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Lenalidomide
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016600
The ClinicalTrials.gov registry entry for NCT01016600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 115-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (73% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT01016600 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01016600 about?
NCT01016600 is a clinical study titled "Azacitidine and Lenalidomide for Acute Myeloid Leukemia". Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
What is the current status of trial NCT01016600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-04. Estimated completion is 2014-10.
What conditions does trial NCT01016600 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT01016600?
The interventions under investigation include: Azacitidine (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01016600?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01016600 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
RECRUITING · Phase 1
-
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
RECRUITING · Phase 1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.